Quintiles has announced that it will provide commercialization services to Pharmaxis for the launch of Pharmaxis’s Bronchitol mannitol DPI for the treatment of Cystic Fibrosis. Bronchitol has received orphan drug status in both Europe and the US, and Pharmaxis has filed an MAA with the EMA. Read the company’s press release.
Quintiles to support Bronchitol commercialization
published on
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
